425: Leading Proxy Firms Endorse iCAD Acquisition by RadNet, Paving Way for Stockholder Vote

Leading independent proxy advisory firms ISS and Glass Lewis have recommended iCAD stockholders vote FOR the proposed all-stock acquisition by RadNet, Inc., citing benefits for stockholders and accelerated deployment of AI solutions.

Summary

• iCAD, Inc. announced that leading independent proxy advisory firms Institutional Shareholder Services Inc. (ISS) and Glass, Lewis & Co. (Glass Lewis) have each recommended that stockholders vote FOR the previously announced acquisition by RadNet, Inc.
• The Special Meeting of Stockholders is scheduled for July 14, 2025, at 9:00 a.m. ET, to be held virtually.
• The acquisition is structured as an all-stock transaction, aiming to accelerate the deployment of iCAD’s ProFound AI breast health solutions across RadNet’s DeepHealth portfolio, expanding access to early breast cancer detection.
• Both ISS and Glass Lewis reviewed the transaction and concluded it is in the best interests of iCAD stockholders, citing the Board's reasonable review of alternatives, the implied premium, and the opportunity for iCAD stockholders to participate in the potential upside of the combined entity.
• iCAD’s Board of Directors also unanimously recommends that stockholders vote FOR the merger and all related matters.
• Stockholders of record as of May 16, 2025, are eligible to vote.

Sentiment

Score: 8

Explanation: The document conveys a highly positive sentiment regarding the proposed acquisition, primarily driven by the strong endorsements from two leading independent proxy advisory firms, ISS and Glass Lewis, and the unanimous recommendation from iCAD's Board of Directors. The stated benefits, such as accelerated deployment of AI solutions and potential upside for stockholders, contribute to this positive outlook, despite the standard inclusion of merger-related risks.

Positives

• Leading independent proxy advisory firms ISS and Glass Lewis recommend voting FOR the acquisition by RadNet, Inc.
• The acquisition is structured to accelerate the deployment of iCAD’s ProFound AI breast health solutions across RadNet’s DeepHealth portfolio.
• The transaction is expected to expand access to early breast cancer detection.
• Proxy firms cited iCAD’s Board’s reasonable review of alternatives in their FOR recommendations.
• The transaction includes an implied premium for iCAD stockholders.
• iCAD stockholders will have the opportunity to participate in the potential upside of the combined entity.
• iCAD’s Board of Directors unanimously recommends that stockholders vote FOR the merger.

Risks

• Termination of the merger agreement or occurrence of any event, change, or circumstances that could give rise to termination or inability to complete the proposed transaction on anticipated terms and timetable.
• Inability to complete the proposed transaction due to failure to obtain iCAD stockholder approval or to satisfy any other condition to closing in a timely manner or at all.
• Risk that a regulatory approval required for the proposed transaction is delayed, not obtained, or obtained subject to unanticipated conditions.
• Inability to recognize the anticipated benefits of the proposed transaction, which may be affected by the ability of RadNet or iCAD to maintain relationships with customers, patients, payers, physicians, and providers, and retain management and key employees.
• Inability of RadNet following the proposed transaction to achieve the synergies contemplated or such synergies taking longer to realize than expected.
• Costs related to the proposed transaction.
• Inability of RadNet following the proposed transaction to successfully execute its strategic plans.
• Inability of RadNet following the proposed transaction to promptly and effectively integrate iCAD into its business.
• Risk of litigation related to the proposed transaction.
• Diversion of management’s time and attention from ordinary course business operations to completion of the proposed transaction and integration matters.
• Risk of legislative, regulatory, economic, competitive, and technological changes.
• Risks relating to the value of RadNet’s securities to be issued in the proposed merger.
• The effect of the announcement, pendency, or completion of the proposed transactions on the market price of the common stock of each of RadNet and iCAD.
• Risks specific to iCAD, including the willingness of patients to undergo mammography screening, whether mammography screening will be treated as an essential procedure, and whether ProFound AI will improve reading efficiency, specificity, sensitivity, reduce false positives, and otherwise prove to be more beneficial for patients and clinicians.
• Impact of supply and manufacturing constraints or difficulties on iCAD’s ability to fulfill orders.
• Uncertainty of future sales levels for iCAD.
• iCAD’s ability to defend itself in litigation matters.
• Protection of iCAD’s patents and other proprietary rights.
• Product market acceptance for iCAD.
• Possible technological obsolescence of iCAD products.
• Increased competition for iCAD.
• Government regulation affecting iCAD.
• Changes in Medicare or other reimbursement policies affecting iCAD.
• Risks relating to iCAD’s existing and future debt obligations.
• Competitive factors affecting iCAD.
• Effects of a decline in the economy or markets served by iCAD.

Future Outlook

The acquisition is expected to accelerate the deployment of iCAD's ProFound AI breast health solutions across RadNet's DeepHealth portfolio, expanding access to early breast cancer detection. The combined entity is anticipated to offer potential upside for iCAD stockholders, and synergies from the proposed transaction are contemplated.

Management Comments

• iCAD's Board of Directors also unanimously recommends that stockholders vote FOR the merger, and all related matters to be voted upon at the Special Meeting.

Industry Context

This acquisition represents a strategic consolidation within the healthcare technology sector, specifically in AI-powered medical imaging and cancer detection. It highlights a growing trend of larger healthcare providers integrating advanced AI solutions to enhance diagnostic capabilities and patient outcomes. RadNet's acquisition of iCAD aims to leverage iCAD's specialized AI for breast health within a broader diagnostic imaging network, potentially setting a precedent for similar integrations in the industry to expand market reach and improve service delivery.

Stakeholder Impact

• Shareholders: Opportunity to participate in the potential upside of the combined entity; implied premium from the all-stock transaction; urged to vote FOR the merger.
• Patients: Expanded access to early breast cancer detection through accelerated deployment of ProFound AI solutions.
• Medical Providers/Clinicians: Enhanced AI-powered solutions for accurate and reliable cancer detection.
• Employees: Potential impact on retention and integration into RadNet's business (mentioned as a risk).
• Customers/Payers/Physicians: RadNet's ability to maintain relationships with these stakeholders is a factor in recognizing anticipated benefits (mentioned as a risk).

Next Steps

• iCAD stockholders are to vote on the proposed acquisition at the Special Meeting on July 14, 2025.
• Completion of the proposed transaction, subject to stockholder approval and other closing conditions.
• Integration of iCAD into RadNet's business post-acquisition.

Key Dates

Recommendation

Keywords

iCAD, RadNet, Merger, Acquisition, Proxy Advisory, ISS, Glass Lewis, Stockholder Vote, AI-powered cancer detection, ProFound AI, Breast Health, Healthcare Technology, Medical Imaging, DeepHealth, NASDAQ: ICAD